Antifungal Pharmacokinetics and Pharmacodynamics

被引:85
|
作者
Lepak, Alexander J. [1 ]
Andes, David R. [1 ]
机构
[1] Univ Wisconsin, Madison, WI 53705 USA
来源
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE | 2015年 / 5卷 / 05期
关键词
INVASIVE PULMONARY ASPERGILLOSIS; LIPOSOMAL AMPHOTERICIN-B; IN-VITRO MODEL; GUINEA-PIG MODEL; HEMATOGENOUS CANDIDA MENINGOENCEPHALITIS; GALACTOMANNAN ENZYME-IMMUNOASSAY; NEUTROPENIC MURINE MODEL; DOSE-DEPENDENT ACTIVITY; COMBINATION THERAPY; LIPID COMPLEX;
D O I
10.1101/cshperspect.a019653
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Successful treatment of infectious diseases requires choice of the most suitable antimicrobial agent, comprising consideration of drug pharmacokinetics (PK), including penetration into infection site, pathogen susceptibility, optimal route of drug administration, drug dose, frequency of administration, duration of therapy, and drug toxicity. Antimicrobial pharmacokinetic/pharmacodynamic (PK/PD) studies consider these variables and have been useful in drug development, optimizing dosing regimens, determining susceptibility breakpoints, and limiting toxicity of antifungal therapy. Here the concepts of antifungal PK/PD studies are reviewed, with emphasis on methodology and application. The initial sections of this review focus on principles and methodology. Then the pharmacodynamics of each major antifungal drug class (polyenes, flucytosine, azoles, and echinocandins) is discussed. Finally, the review discusses novel areas of pharmacodynamic investigation in the study and application of combination therapy.
引用
收藏
页数:23
相关论文
共 50 条
  • [1] Pharmacokinetics and Pharmacodynamics of Antifungal Agents in Neonates and Children
    Antachopoulos, Charalampos
    Roilides, Emmanuel
    CURRENT FUNGAL INFECTION REPORTS, 2020, 14 (03) : 317 - 328
  • [2] Pharmacokinetics and pharmacodynamics of antifungal drugs in children
    Jullien, V.
    ARCHIVES DE PEDIATRIE, 2011, 18 : S42 - S47
  • [3] Assessment of Antifungal Pharmacodynamics
    Howard, Alex
    Hope, William
    JOURNAL OF FUNGI, 2023, 9 (02)
  • [4] Preclinical Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antifungal Activity of Liposomal Amphotericin B
    Adler-Moore, Jill
    Lewis, Russell E.
    Bruggemann, Roger J. M.
    Rijnders, Bart J. A.
    Groll, Andreas H.
    Walsh, Thomas J.
    CLINICAL INFECTIOUS DISEASES, 2019, 68 : S244 - S259
  • [5] Pharmacokinetics-pharmacodynamics of antifungal agents in the central nervous system
    Stott, Katharine E.
    Hope, William
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2018, 14 (08) : 803 - 815
  • [6] Antifungal pharmacokinetics and pharmacodynamics: bridging from the bench to bedside
    Hope, W. W.
    Drusano, G. L.
    CLINICAL MICROBIOLOGY AND INFECTION, 2009, 15 (07) : 602 - 612
  • [7] Antifungal pharmacodynamics: Latin America's perspective
    Gonzalez, Javier M.
    Rodriguez, Carlos A.
    Agudelo, Maria
    Zuluaga, Andres F.
    Vesga, Omar
    BRAZILIAN JOURNAL OF INFECTIOUS DISEASES, 2017, 21 (01): : 79 - 87
  • [8] Pharmacodynamics and Pharmacokinetics of Antifungals for Treatment of Invasive Aspergillosis
    Bellmann, Romuald
    CURRENT PHARMACEUTICAL DESIGN, 2013, 19 (20) : 3629 - 3647
  • [9] Pharmacodynamics for antifungal drug development: an approach for acceleration, risk minimization and demonstration of causality
    Hope, William
    Drusano, George L.
    Rex, John H.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2016, 71 (11) : 3008 - 3019
  • [10] Pharmacokinetics and Pharmacodynamics of Posaconazole
    Chen, Lu
    Krekels, Elke H. J.
    Verweij, Paul E.
    Bui, Jochem B.
    Knibbe, Catherijne A. J.
    Bruggemann, Roger J. M.
    DRUGS, 2020, 80 (07) : 671 - 695